Filling the need for trusted information on national health issues

GSK’s HIV Unit May Cease Operations In Future If HIV Treatments Continue To Be Effective, ViiV Healthcare Chair Says

Bloomberg Business: Success at Glaxo’s HIV Unit May Mean Having to Call It Quits
“HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose. ‘There are diminishing returns in HIV,’ said David Redfern, Glaxo’s chief strategy officer and the chairman of its AIDS treatment unit ViiV Healthcare Ltd. ‘The industry has done a fantastic job of taking the fear of the late ’80s, and the death sentence, and taking that to one tablet a day’…” (Staley, 7/9).